603351.SH
威尔药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 26.39
−1.31%Year over year
Reported trailing growth
- Revenue
- +1.9%
- EBITDA
- —
- EBIT
- -0.3%
- EPS
- +2.8%
- Free cash flow
- +19.0%
- Operating cash flow
- +8.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +6.3%
- EBITDA
- +18.6%
- EBIT
- +15.2%
- Net income
- +16.7%
- EPS
- +15.5%
- Free cash flow
- +98.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026